Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-08-28 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "东北制药集团股份有限公司2022 年半年度财务报告" which translates to "Northeast Pharmaceutical Group Co., Ltd. 2022 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year (semi-annual) financial report and includes substantive financial data and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-28 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 90% confidence The document is a statement by independent directors regarding related party transactions and external guarantees for the half-year period ending June 30, 2022. It references regulatory guidelines and confirms compliance and absence of non-operating fund occupation or unauthorized guarantees. The document is short (464 characters) and serves as a special explanation and independent opinion rather than a full financial report. It does not contain detailed financial statements or comprehensive analysis. This fits the category of an Audit Report / Information (AR), which includes standalone audit reports and related regulatory compliance statements, excluding full annual or interim reports. H1 2022
2022-08-28 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the first half of 2022 by Northeast Pharmaceutical Group Co., Ltd. It includes financial figures such as balances, amounts incurred, interest, repayments, and ending balances. The document is relatively short (2265 characters) and focuses on specific financial data related to related party transactions and fund usage for a half-year period. This matches the characteristics of an Interim / Quarterly Report (IR), which contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not an announcement or a certification, but actual financial data presentation. Therefore, the correct classification is IR. H1 2022
2022-08-28 Chinese
关于盐酸金刚烷胺片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (盐酸金刚烷胺片) passing a generic drug consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, and potential impact on the company. There is no financial data, no mention of financial results, no management discussion, no shareholder voting, no capital changes, or other financial report content. The document is a regulatory announcement about product approval and related business impact, typical of a general regulatory filing. The document length is short (968 characters), and it is not an announcement of a report publication but a substantive announcement itself. Therefore, the best fitting category is Regulatory Filings (RNS).
2022-08-25 Chinese
关于召开公司2022年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2022 second extraordinary general meeting of shareholders, including meeting details, voting procedures, and proxy forms. It does not contain financial statements or results, nor is it a transcript or report of the meeting outcomes. It is a notice informing shareholders about the meeting and how to participate, which fits the definition of a Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, and it is not announcing the publication of a report but providing meeting and voting information.
2022-08-25 Chinese
第九届监事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Northeast Pharmaceutical Group Co., Ltd. It details the meeting date, attendance, and voting results on specific company matters such as signing a supplementary agreement and asset disposal. It does not contain financial statements, audit opinions, or detailed financial data. It is not an annual or interim report, nor a call transcript or earnings release. The document is a formal announcement of board/management decisions and meeting resolutions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on meeting resolutions, not a report publication or regulatory filing. Confidence is high due to clear meeting and voting details.
2022-08-14 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.